A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity

Annals of the New York Academy of Sciences

Volumn 850, Issue , 1998, Pages 483-487

  Porter, J B ^a   Faherty, A ^a   Stallibrass, L ^b   Brookman, L ^b   Hassan, I ^b   Howes, C ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Research Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; IRON CHELATE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; CHELATION THERAPY; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HUMAN; IRON OVERLOAD; MALE; OTOTOXICITY; VISUAL IMPAIRMENT;

EID: 0031873072     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1998.tb10528.x     Document Type: Conference Paper

References (7)

1. PORTER, J. B. & E. R. HUEHNS. 1989. The toxic effects of desferrioxamine. Clin Haem 2: 459-474.
2. PORTER, J. B., et al. 1989. Desferrioxamine ototoxicity: Evaluation of risk factors in thalassaemic patients and guicdlines for safe dosage. Brit. J. Haemal. 73:403-405.
3. OLIVIERI, N. F., et al. 1992. Growth failure and bony changes induced by defenoxamine. Am. J. Ped. HematolVOnc. 14(1): 48-56.
4. PORTER, J. B. et al. 1992. Osteopaenia thalassaemia major: The relevance of desferrioxamine drug metabolism, (abstract) 24th International Society of Haematology 1992,184(7).
5. KRUCK, T. P. A. et al. 1993. A predictor for side effects in patients with Alzheimers disease treated with deferoxamine mesylate. Clin. Pharmacol. Then 53: 30-7.
6. ARDEN, G. B. et al. 1989. Ocular changes in patients following long term desferrioxamine treatment. Brit. J. Opthal. 68: 873-877.
7. LEE, P. et al. 1993. Intravenous infusion pharmacokinetics of Desferrioxamine in thalassaemia patients. Drug Metab. Dispos. 21(4): 640-644.